Abstract:Background: Treatment of urethral trauma is currently done after urethral stricture occurs. Stricture therapy after occurrence gives unsatisfactory success rates. Several genes, such as transforming growth factor beta 1 (TGF-β1), matrix metalloproteinase 1 (MMP-1), connective tissue growth factor (CTGF), and plasminogen activator inhibitor 1 (PAI-1), have a proven role in urethral stricture development. The purpose of this study was to assess the effect docetaxel and/or captopril on the RNA expression of those genes. Methods: The subjects of this research were 26 male New Zealand rabbits aged 230 ± 20 days weighing 4–5 kg that underwent urethral rupture by endoscopic resection under anesthetized conditions. Subjects were divided into five groups; control, stricture, captopril (captopril 0.05 mg/rabbit/day), docetaxel (docetaxel 0.1 mg/rabbit/day), and docetaxel-captopril (docetaxel 0.1 mg/rabbit/day and captopril 0.05 mg/rabbit/day). Each group consisted of 4–6 rabbits. Each rabbit received a water-soluble transurethral gel containing drug according to its group for 28 days. After the treatment period, rabbits were sacrificed with 200 mg Pentothal, and the corpus spongiosum was then prepared for real-time PCR examination. Results: TGF-β1 RNA expression in the stricture group was statistically different from that in the control, docetaxel and docetaxel-captopril groups ( p = 0.016; p = 0.016; p = 0.004). The stricture group did not exhibit any statistical difference from the captopril group ( p = 0.190). The control group did not show any statistically difference from the captopril, docetaxel, and docetaxel-captopril groups ( p = 0.114; p = 0.190; p = 1.000). Docetaxel-captopril suppresses expression of TGF-β1 RNA most significantly. MMP-1 RNA expression showed no significant differences among groups ( p = 0.827). The docetaxel group and stricture group pair was most significant ( p = 0.247), compared with other pairs of stricture groups in MMP-1 RNA expression. CTGF RNA expression in the stricture group was statistically different from that of control, captopril, docetaxel, and docetaxel-captopril groups ( p = 0.003; p = 0.019; p = 0.005; p = 0.005). The control group did not exhibit any statistically difference from the captopril, docetaxel, and docetaxel-captopril groups ( p = 0.408; p = 0.709; p = 0.695). There was no statistical difference among treatment groups. Docetaxel and docetaxel-captopril groups suppress the most significant expression of CTGF RNA expression. PAI-1 RNA expression in the stricture group differed statistically significantly from the control and docetaxel groups ( p = 0.044; p = 0.016). The stricture group did not show any statistically significant difference from the captopril and docetaxel-captopril groups ( p = 0.763; p = 0.086). The control group did not exhibit any statistical difference with any of the treatment groups ( p = 0.101; p = 0.637; p = 0.669). Conclusion: Docetaxel-captopril gel proved to be able to inhibit RNA expression of TGF-β1 and CTGF significantly. Captopril gel proved to be able to inhibit RNA expression of CTGF significantly. Docetaxel gel proved to be able to inhibit RNA expression of TGF-β1, CTGF, and PAI-1 significantly. There were no differences in MMP-1 expression among all study groups. Longer follow up after therapy discontinuation and greater sample size is needed to determine the therapeutic effect.

Study of the effect of Matrine on urethral stricture formation in rabbits

Effect of Matrine and Carvedilol on Collagen and MMPs Activity of Hypertrophy Myocardium Induced by Pressure Overload

Development and Characterization of Urethral Stricture Model in Rabbits

Effect of matrine and crataegus mixture on connective tissue growth factor in unilateral ureteral obstruction rats

Docetaxel Inhibits Urethral Stricture Formation, an Initial Study in Rabbit Model.

The effects of docetaxel and/or captopril in expression of TGF-β1, MMP-1, CTGF, and PAI-1 as markers of anterior urethral stricture in an animal model

Role of matrine in renal interstitial fibrosis after unilateral ureteral obstruction in rats

The Effects and Mechanisms of the Rapamycin-eluting Stent in Urethral Stricture Prevention in Rabbits

[Experimental Study on Effect of Matrine in Alleviating Renal Tubulointerstitial Fibrosis in Unilateral Ureteral Obstruction Model].

Establishment of urethral stricture in rabbit model with visual endoscopic urethroelectrocoagulation

Rapamycin Inhibits Formation of Urethral Stricture in Rabbits

An Experimental Model of Anterior Urethral Stricture in Rabbits With Local Injections of Bleomycin

[Renoprotective Effects of Matrine on Experimental Glomerulosclerosis in Rats].

Decreased Urethral Mucosal Damage And Delayed Bacterial Colonization During Short-Term Urethral Catheterization Using A Novel Trefoil Urethral Catheter Profile In Rabbits

Three New Experimental Models of Anterior Urethral Stricture in Rabbits.

[Effect of Matrine on Regulating Renal Tubulointerstitial Expression of MMP-3, TIMP-1 and FN].

Effect of uncultured adipose-derived stromal vascular fraction on preventing urethral stricture formation in rats

Establishment of a stable urethral stricture model in New Zealand rabbits | Establecimiento de un modelo estable de estenosis uretral en conejos de Nueva Zelanda

Inhibitive Effect of Matrine on the Growth of Subcutaneous Implanted Tumor Model of ACHN Renal Cell Carcinoma in Nude Mice

New Biodegradable Drug-Eluting Stents for Urethral Strictures in a Rabbit Model

Biodegradable drug-eluting urethral stent in limiting urethral stricture formation after urethral injury: An experimental study in rabbit